Coherus presents preliminary results from phase i dose escalation study of its anti-chemokine receptor 8 (ccr8) antibody, chs-114, at the 2024 american society of clinical oncology (asco) annual meeting

Chs-114 shown to have an acceptable safety profile with no dose-limiting toxicities (dlts) in heavily pretreated patients with solid tumors
CHSCP Ratings Summary
CHSCP Quant Ranking